Literature DB >> 8028868

Hyperbaric oxygen treatment of osteoradionecrosis of the mandible with repeated pathologic fracture. Report of a case.

J P van Merkesteyn1, A J Balm, D J Bakker, A M Borgmeyer-Hoelen.   

Abstract

Treatment of patients with osteoradionecrosis of the mandible with a pathologic fracture consists in almost all cases of a continuity resection of the mandible. This leads to functional and esthetic problems that can only be solved by often extensive surgery. In this case report we present a 38-year-old woman who developed osteoradionecrosis of the mandible with a pathologic fracture 1 1/2 years after combined surgical and radiation therapy of an adenocarcinoma of the right parotid gland. The patient had a subcondylar pathologic fracture together with osteolysis in the right mandibular body, normally an indication for partial resection of the mandible. Because of the absence of denuded bone, fistulation, and the poor quality of the surrounding soft tissues, a more conservative approach was chosen. Treatment consisted of hyperbaric oxygen and dental extractions with alveolectomy with the patient under local anesthesia. During follow-up, a second pathologic fracture occurred in the region of the right first and second molar. No additional treatment was given. Six and one-half years after the initial treatment and 5 1/2 years after the last fracture, the patient is free of complaints, the fractures have healed and both esthetic and functional results are good.

Entities:  

Mesh:

Year:  1994        PMID: 8028868     DOI: 10.1016/0030-4220(94)90224-0

Source DB:  PubMed          Journal:  Oral Surg Oral Med Oral Pathol        ISSN: 0030-4220


  1 in total

1.  Radiographic osteoradionecrosis of the jaw with intact mucosa: Proposal of clinical guidelines for early identification of this condition.

Authors:  Adepitan A Owosho; Arvin Kadempour; SaeHee K Yom; Joseph Randazzo; C Jillian Tsai; Nancy Y Lee; Ashok R Shaha; Joseph M Huryn; Cherry L Estilo
Journal:  Oral Oncol       Date:  2015-10-09       Impact factor: 5.337

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.